ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES

1 . A composition for inhibiting the expression of Beta-Catenin, the composition comprising a RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the antisense strand of a RNAi agent provided in Table 1, Table 2, or Table 3, and the sense strand is substantially complementary to the antisense strand.

2 . The composition of claim 1 , wherein the composition further comprises a second RNAi agent to Beta-Catenin.

3 . The composition of claim 1 , wherein the RNAi agent comprises at least one modified backbone and/or at least one 2′-modified nucleotide.

4 . The composition of claim 1 , wherein the RNAi agent is ligated to one or more agent selected from: diagnostic compound, reporter group, cross-linking agent, nuclease-resistance conferring moiety, natural or unusual nucleobase, lipophilic molecule, cholesterol, lipid, lectin, steroid, uvaol, hecigenin, diosgenin, terpene, triterpene, sarsasapogenin, Friedelin, epifriedelanol-derivatized lithocholic acid, vitamin, carbohydrate, dextran, pullulan, chitin, chitosan, synthetic carbohydrate, oligo lactate 15-mer, natural polymer, low- or medium-molecular weight polymer, inulin, cyclodextrin, hyaluronic acid, protein, protein-binding agent, integrin-targeting molecule, polycationic, peptide, polyamine, peptide mimic, and/or transferrin.

5 . The composition of claim 1 , wherein the RNAi agent comprieses a sense strand and an anatisense strand, wherein the antisense strand comprises the nucleotide sequence of any of the antisense strand sequences provided in Table 1, Table 2, or Table 3.

6 . The composition of claim 5 , wherein the sense strand comprises the nucleotide sequence of any of the sense strand sequences provided in Table 1, Table 2, or Table 3.

7 . The composition of claim 5 , wherein the RNAi agent comprises a phosphorothioate and/or a 2′-modified nucleotide.

8 . The composition of claim 1 , wherein the RNAi agent is ligated to one or more agents, the agent selected from a: diagnostic compound, reporter group, cross-linking agent, nuclease-resistance conferring moiety, natural or unusual nucleobase, lipophilic molecule, cholesterol, lipid, lectin, steroid, uvaol, hecigenin, diosgenin, terpene, triterpene, sarsasapogenin, Friedelin, epifriedelanol-derivatized lithocholic acid, vitamin, carbohydrate, dextran, pullulan, chitin, chitosan, synthetic carbohydrate, oligo lactate 15-mer, natural polymer, low- or medium-molecular weight polymer, inulin, cyclodextrin, hyaluronic acid, protein, protein-binding agent, integrin-targeting molecule, polycationic, peptide, polyamine, peptide mimic, and/or transferrin.

9 . A method of treating a Beta-Catenin-related disease in an individual, comprising the step of administering to the individual a therapeutically effective amount of a composition comprising a RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the antisense strand of a RNAi agent specific to Beta-Catenin provided in Table 1, Table 2, or Table 3.

10 . The method of claim 9 , wherein the Beta-Catenin-related disease is selected from: adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, and chronic wounds and impaired wound healing.

11 . The method of claim 9 , wherein the method further comprises the step of administering an additional treatment for adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, and/or chronic wounds and impaired wound healing.

12 . The method of claim 11 , wherein the method further comprises the step of administering an additional RNAi agent to Beta-Catenin.

13 . A method of inhibiting the expression of the Beta-Catenin gene in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a composition comprising a RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the antisense strand of a RNAi agent specific to Beta-Catenin provided in Table 1 Table 2, or Table 3.

14 . The method of claim 13 , wherein the Beta-Catenin-related disease is adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, and chronic wounds and/or impaired wound healing.

15 . The composition according to claim 1 in a pharmaceutically effective formulation.

16 . The composition of claim 1 , wherein all the pyrimidines are 2′ O-methyl-modified nucleotides.

17 . The composition of claim 5 , wherein all the pyrimidines are 2′ O-methyl-modified nucleotides.